Drug Trial Radar · NCT02944448
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
Last checked: Nov 19, 2026Latest source record: Oct 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
761
Actual
Start
Sep 2016
Primary completion
May 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study schedule consists of a Screening Period (up to 14 days), a blinded 4- week Titration-to-Effect Period with weekly visits, a blinded 4-week Maintenance Treatment Period at the optimal dose level determined for each patient, and a 1-week Follow-up Period. Eligible patients will be randomized to receive either CR845 or placebo in a 2:1 ratio. Every patient will be started on a 1-mg dose of CR845 or matching placebo. During the post-randomization Titration-to-Effect period, the dose of study drug may be increased to 2.5 mg or 5 mg in a double-blind fashion. Patients may know their dose is being changed but will not know whether they were randomization to active study drug or placebo. Approximately 330 patients will be enrolled in this study.
Conditions
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Arthritis
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
Interventions
CR845 tablet 1 mgDrug
CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
CR845 tablet 2.5 mgDrug
CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
CR845 tablet 5 mgDrug
CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Placebo tabletDrug
Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline at Week 8 With Respect to the Weekly Mean of the Daily 24-hour Pain Intensity for the Index Joint as Measured by the Numeric Rating Scale (NRS).Time frame: Baseline, Week 8
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Birmingham, Alabama
Cara Therapeutics Study Site
Peoria, Arizona
Cara Therapeutics Study Site
Phoenix, Arizona
Cara Therapeutics Study Site
Carmichael, California
Cara Therapeutics Study Site
San Diego, California
Cara Therapeutics Study Site
Tustin, California
Cara Therapeutics Study Site
Homestead, Florida
Cara Therapeutics Study Site
Jupiter, Florida
Cara Therapeutics Study Site
Lake Worth, Florida
Cara Therapeutics Study Site
Miami, Florida
Cara Therapeutics Study Site
Oldsmar, Florida
Cara Therapeutics Study Site
Orlando, Florida
Cara Therapeutics Study Site
Plantation, Florida
Cara Therapeutics Study Site
South Miami, Florida
Cara Therapeutics Study Site
Tampa, Florida
Cara Therapeutics Study Site
Savannah, Georgia
Cara Therapeutics Study Site
Hazelwood, Missouri
Cara Therapeutics Study Site
Omaha, Nebraska
Cara Therapeutics Study Site
Las Vegas, Nevada
Cara Therapeutics Study Site
Berlin, New Jersey
Cara Therapeutics Study Site
Binghamton, New York
Cara Therapeutics Study Site
Rochester, New York
Cara Therapeutics Study Site
Cincinnati, Ohio
Cara Therapeutics Study Site
Cincinnati, Ohio
Cara Therapeutics Study Site
Oklahoma City, Oklahoma
Cara Therapeutics Study Site
Duncansville, Pennsylvania
Cara Therapeutics Study Site
Charleston, South Carolina
Cara Therapeutics Study Site
Charleston, South Carolina
Cara Therapeutics Study Site
Greenville, South Carolina
Cara Therapeutics Study Site
Austin, Texas
Cara Therapeutics Study Site
Dallas, Texas
Cara Therapeutics Study Site
Plano, Texas
Cara Therapeutics Study Site
Plano, Texas
Cara Therapeutics Study Site
San Antonio, Texas
Cara Therapeutics Study Site
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.